Cerenis Therapeutics

Pipeline

Cerenis is developing a broad pipeline of HDL therapies to address the needs of a variety of patients in both the sub-acute and chronic care cardiovascular disease (CVD) markets.

For severe atherosclerosis patients, Cerenis is developing intravenous (IV) infusion products designed to rapidly regress atherosclerotic plaque. For patients with dyslipidemia and low HDL, Cerenis is developing oral therapies for enhancement of HDL function. In both categories, the goal is to dramatically reduce cardiovascular morbidity and mortality beyond what is possible with current therapies.

header Sub-Acute (IV infusion products designed to rapidly regress atherosclerotic plaque) CER-001 CER-522 Chronic (oral products designed to enhance HDL function) CER-627 CER-628 CER-002 HDL Receptor Enhancer